X4 Pharmaceuticals

Contributing Author

Recent Articles by X4 Pharmaceuticals

Nov-05	X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference XFOR GlobeNewswire
Nov-05	X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update XFOR GlobeNewswire
Oct-27	X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million XFOR GlobeNewswire
Oct-24	X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering XFOR GlobeNewswire
Oct-23	X4 Pharmaceuticals Announces Proposed Underwritten Public Offering XFOR GlobeNewswire
Sep-17	X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation XFOR GlobeNewswire
Aug-15	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
Aug-13	X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement XFOR GlobeNewswire
Aug-12	X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership XFOR GlobeNewswire
Jun-16	X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) XFOR GlobeNewswire
Jun-10	X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA XFOR GlobeNewswire
Jun-02	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
May-14	X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress XFOR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.